Nathan Cali
About Nathan Cali
Nathan Cali is a co-founder of Precise Bio and currently serves as a committee member at Moffitt Cancer Center. With extensive experience in finance and biotechnology, he has held leadership roles at NOBLE Capital Markets and ZyVersa Therapeutics Inc.
Work at ZyVersa Therapeutics
Nathan Cali serves as a Co-Founder at ZyVersa Therapeutics Inc., a role he has held since 2014. The company, located in Weston, Florida, focuses on developing innovative therapies for unmet medical needs. Under his leadership, ZyVersa Therapeutics aims to advance its pipeline of drug candidates, contributing to the field of biotechnology.
Current Role at Moffitt Cancer Center
Since 2018, Nathan Cali has been a Committee Member at Moffitt Cancer Center in the Tampa/St. Petersburg, Florida area. His involvement supports the center's mission to advance cancer research and treatment. His expertise in biotechnology and healthcare investment banking informs his contributions to the committee.
Education and Expertise
Nathan Cali holds an MBA in Finance and Real Estate from Nova Southeastern University, which he completed from 2006 to 2008. He also earned a Bachelor of Science in Finance from Florida State University, studying from 1996 to 2000. His educational background supports his expertise in bioengineering concepts and biomaterials, particularly in the context of healthcare solutions.
Professional Background
Nathan Cali has held various positions in the finance and biotechnology sectors. He worked as a Financial Analyst at Franklin Templeton Investments from 2007 to 2008 and served as a Regulatory Manager at Andrx Pharmaceuticals from 2002 to 2006. He also spent eight years at NOBLE Capital Markets, first as Managing Director in Biotechnology/Specialty Pharmaceuticals from 2008 to 2016 and later as Managing Director, Head of Healthcare Investment Banking, Merchant Banking since 2016.
Achievements at Precise Bio
Nathan Cali co-founded Precise Bio, which utilizes a 4D printing platform for bio-fabrication of tissues. Since 2022, he has been involved in the development of tissue engineering technologies at Precise Bio. His role includes integrating cell technologies into the company's healthcare solutions, which are applicable in various fields such as cardiology, orthopedics, and dermatology.